【摘 要】
：
Objective: To systematically review the efficacy and safety of Buzhong Yiqi Tang (BZYQT) for the treatment of stable chronic obstructive pulmonary disease (COPD).Methods: Three electronic English data
【机 构】
：
Guangdong Provincial Academy of Chinese Medical Sciences,Guangzhou 510120,China;Guangdong Provincial
【出 处】
：
全国第十九次中医肺系病学术交流会暨2015年浙江省中医药学会呼吸病分会学术年会
论文部分内容阅读
Objective: To systematically review the efficacy and safety of Buzhong Yiqi Tang (BZYQT) for the treatment of stable chronic obstructive pulmonary disease (COPD).Methods: Three electronic English databases (PubMed,EMBASE and CENTRAL) and four Chinese databases (CBM,CNKI,VMIS and WFMO) were searched from their inceptions until 30th April 2014.Participants were diagnosed with COPD according to the Chinese medical associations COPD diagnosis and treatment guidelines or Global Initiative for Chronic Obstructive Lung Disease (GOLD),and they were in stable stage.Randomized controlled trials of oral BZYQT,given alone or in combination with conventional therapy,pulmonary rehabilitation,when compared with placebo,pulmonary rehabilitation or conventional therapy were included in the review.Clinical improvement was chosen as the primary outcome.The Cochrane Risk of Bias tool was used to assess methodological quality.Data were analyzed using RevMan 5.3.0 software.Results: Twelve studies involving 900 participants were included.The results of meta-analysis indicate patients receiving BZYQT alone or BZYQT in combination with conventional therapy showed a significant increase in clinical improvement (RR 1.38,95% CI 1.23 to 1.54) and reduced respiratory muscle fatigue (MD 0.46,95% CI 0.11 to 0.80) when compared with conventional therapy alone; BZYQT plus pulmonary rehabilitation improved quality of life (Cais Questionnaire) compared with pulmonary rehabilitation alone (MD -0.62,95% CI -0.73 to -0.52).BZYQT also showed small but significant improvements in exercise capacity and decreased acute exacerbations of COPD.Three studies reported that no adverse events occurred,other studies did not mention the adverse events.Interpretation of research results needs to be considered with caution because the included studies had methodological shortfalls.Conclusions: BZYQT improves clinically important outcomes for patients with stable COPD.However further evaluation is still needed to validate these preliminary finding in high quality randomized controlled trials.
其他文献
目的：了解某院门诊高血压患者抗高血压药的使用情况,并对其进行分析,为临床合理用药提供参考.方法：随机抽取某院2013年10月-12月的门诊抗高血压药处方2168张进行统计分析.结果：临床使用量和使用率最多的口服抗高血压药类别都是钙离子拮抗剂(CCB),而后依次是血管紧张素Ⅱ受体阻滞剂(ARB)、β受体阻滞剂、利尿剂、血管紧张素转化酶抑制剂(ACEI).使用量和使用率前三的抗高血压药物品种依次是氨氯
目的：探讨临床药师在华法林抗凝治疗中发挥的作用.方法：收集134例心脏机械瓣膜置换术后服用华法林抗凝患者的临床资料,比较抗凝初期临床药师参与抗凝管理及医师单独进行抗凝治疗对患者抗凝效果的影响,及不良反应的发生率;术后药师随访与非随访组的患者抗凝效果比较.结果：干预组与对照组患者一般情况无显著性差异,患者的主要观察指标首次达到目标INR值的时间,住院期间INR在范围的时间及INR小于治疗窗的时间比例
本文分析了本院失眠患者用药教育的现状,分析了药师在失眠症患者教育中的作用和优势,探讨了药师开展失眠患者教育的工作方法.针对目前失眠患者药物使用的状况，加强就诊时的健康教育指导十分必要，可以利用门诊导诊、健康教育处方、健康教育报栏等形式，为患者提供健康教育指导。不但临床医生要重视，临床药师也应该参与其中，努力做好这类患者的健康教育指导，帮助他们认清苯二氮卓类药物滥用的危害，采用综合治疗的手段，科学、
目的：建立高效液相色谱法同时测定血浆中奥卡西平(Oxcarbazepine,OXC)及其活性代谢物10-羟基卡马西平(Monohydroxy carbamazepine,MHD)的浓度.方法：采用Phenomenex C18柱(250nm×4.6nm,5um)分离,柱温32℃,流动相：甲醇-水(0.55：0.35),流速0.9mL·min-1,检测波长210nm.艾司唑仑作为内标,血浆样品经二氯甲
疾病是动态变化的,百病由气生,气机升降出入运动疾病也随之相应变化;时节气性生化的太过与不及,疾病也随之相应.风寒暑湿燥火各有其相应的主时.人与自然息息相关,六气与时节相宜则人安,六气与时节不相宜则人病.诚如张景岳所注:“病随气动,必察其机,治之得其要,是无失气宜也.”《皇汉医学》:“医有上工下工,对病欲愈,执方欲加者,谓之下工.临证察机,使药要和者,谓之上工.夫察机要和者,似迂而反捷.”.医生不懂
王氏温架透灸是在雷火神针的基础上，融合了十几味地道中药材，精工做成直径约4cm粗细的药条，特制的灸架，可插3-16根艾柱，渗透力提高80-100倍，药力跟随热力可穿透深部组织，以短时间、近距离、高温度、大面积、药力峻、渗透力极强而称王，远非一般灸法所能及。功效：温补督阳、强壮真元、调和阴阳、温通气血、化瘤散瘿、祛风除湿、消肿止痛。王廷峰立足于中医基础理论和古代灸法技术，认为充足的灸量是得气取效的前
本文从文献角度与医学原理,分析了《素问·至真要大论》“诸痛痒疮,皆属于心”一句中的“痒”字,对历代医家的理解作了疏解,并结合当代学者的观点展开了探讨.《素问·举痛论》：“思则气结……思则心有所存，神有所归，正气留而不行，故气结矣。”指出忧思会使正气不行，从而气结致病。唐·王冰《重广补注黄帝内经素问》注：“心寂则痛微，心躁则痛甚。百端之起，皆自心生。痛痒疮疡，生于心也。”王冰指出“痛痒疮疡，生于心也
《伤寒杂病论》之所以历久弥新,一直指导着临床并成为医家研究的热点,这与其编撰的科学性、系统性、条理性、实用性、针对性及可读性是密不可分的,可以说这部伟大的著作正是一部完美的中医教科书.是因为其中不仅有“鱼”,而且有“渔”,仲景在编撰时,将前人经验及个人平生所学、临床经验皆融入其中,遵循先易后难,由浅及深、由表及里、循序渐进的原则引导后学者,务在示人以法.从典型的桂枝汤证,到桂枝加厚朴杏子汤证,到桂
目的：研究“哮喘病点穴快速疗法”治疗支气管哮喘慢性持续期的临床疗效以及对肺功能的影响.方法：将60例确诊为支气管哮喘慢性持续期患者随机分为治疗组与对照组,每组各30例,治疗组用“哮喘病点穴快速疗法”,首次点穴治疗1小时,后连续点穴治疗40次,每日1次,每次40分钟.疗程40天,随访1年;对照组予”阿斯美”2粒,每日3次,口服.疗程7天,随访1年.观察两组患者治疗前后的临床疗效及肺功能变化.结果：研
Tracheobrochopathia Osteochondroplastica (TO) is a rare but benign disorder affecting the airway and regarded as rare etiology for chronic cough.TO could be easily underdiagnosed or misdiagnosed.It is